298680-25-8
298680-25-8
Chemical Structure
(E/Z)-Ensifentrine
Synonym(s): (E/Z)-RPL-554
- CAS No.: 298680-25-8
- Formula:C26H31N5O4
- Molecular Weight:477.56
IUPAC Name: (E)-1-(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea
InChIKey: CSOBIBXVIYAXFM-BYNJWEBRSA-N
SMILES: O=C(N)NCCN1C(N(CCC2=C3C=C(OC)C(OC)=C2)C3=C/C1=N\C4=C(C)C=C(C)C=C4C)=O
Biological Activity: (E/Z)-Ensifentrine ((E/Z)-RPL-554) is the E/Z isomer of Ensifentrine (HY-119708). Ensifentrine is an inhaled dual PDE3 and PDE4 inhibitor. Ensifentrine can be used in research on chronic obstructive pulmonary disease (COPD)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(E/Z)-Ensifentrine | (E/Z)-Ensifentrine ((E/Z)-RPL-554) is the E/Z isomer of Ensifentrine (HY-119708). Ensifentrine is an inhaled dual PDE3 and PDE4 inhibitor. Ensifentrine can be used in research on chronic obstructive pulmonary disease (COPD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Victoria Boswell-Smith, et al. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J Pharmacol Exp Ther. 2006 Aug;318(2):840-8. [Content Brief]
- [2]. Henrik Watz, et al. Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis. Int J Chron Obstruct Pulmon Dis. 2020 Sep 16;15:2199-2206. [Content Brief]
- [3]. Anzueto A, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-416. [Content Brief]
